TMPRSS2 Inhibitor Discovery Facilitated through an In Silico and Biochemical Screening Platform
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
-
SciScore for 10.1101/2021.03.22.436465: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Antibodies Sentences Resources TMPRSS2 antibody (Novus biologicals, NBP1-20984) was added to membrane (1:1000 dilution in Super Block) and incubated overnight at 4C with gentle shaking. TMPRSS2suggested: (Novus Cat# NBP1-20984, RRID:AB_1643199)Software and Algorithms Sentences Resources Raw data was deconvoluted (intact protein of 20,000-25,000 Da) using BioConfirm software with background subtraction. BioConfirmsuggested: NoneV0 was plotted vs substrate concentration and the data was fit to the Michaelis Menten equation using GraphPad Prism. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect …
SciScore for 10.1101/2021.03.22.436465: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Antibodies Sentences Resources TMPRSS2 antibody (Novus biologicals, NBP1-20984) was added to membrane (1:1000 dilution in Super Block) and incubated overnight at 4C with gentle shaking. TMPRSS2suggested: (Novus Cat# NBP1-20984, RRID:AB_1643199)Software and Algorithms Sentences Resources Raw data was deconvoluted (intact protein of 20,000-25,000 Da) using BioConfirm software with background subtraction. BioConfirmsuggested: NoneV0 was plotted vs substrate concentration and the data was fit to the Michaelis Menten equation using GraphPad Prism. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
-